{"Clinical Trial ID": "NCT01827787", "Intervention": ["INTERVENTION 1:", "Cohort 1: HR+/HER2-", "Uribulin: 1.4 mg/m2 administered intravenously for 2-5 minutes on days 1 and 8 of each 21-day cycle", "The participants remained under a single agent, eribulin, until the disease progressed or retired for other reasons.", "INTERVENTION 2:", "Cohort 2: NBTC", "Uribulin: 1.4 mg/m2 administered intravenously for 2-5 minutes on days 1 and 8 of each 21-day cycle", "The participants remained under a single agent, eribulin, until the disease progressed or retired for other reasons."], "Eligibility": ["Incorporation criteria:", "Invasive breast cancer, locally recurrent or metastatic, proven histologically or cytologically, with at least one measurable lesion according to RECIST v1.1", "\u00b7 Positive hormone receptor or negative hormone receptor HER2-negative disease", "Up to a prior line of chemotherapy for advanced disease is allowed (deleted at least 14 days prior to initiation of protocol therapy)", "The anterior bevacizumab in the neo/adjuvant or metastatic setting is acceptable", "No limit on previous endocrine treatment lines, but should be discontinued at least 7 days prior to initiation of protocol therapy.", "\u2022 Must have completed prior radiation therapy at least 2 weeks prior to the start of protocol therapy", "Of which the reversible effects of previous treatments should not exceed Grade 1 toxicity, with the exception of alopecia.", "To agree to use adequate contraception for the duration of the study", "- Exclusion criteria:", "Pregnant or breast-feeding", "Previous treatment with eribulin", "A prior malignancy other than in situ carcinoma of skin cancer of the cervix or non-melanoma, unless it has been diagnosed and permanently treated at least 3 years prior to inclusion in this study.", "Clinically significant cardiovascular impairment", "\u2022 Active brain metastases or unevaluated neurological symptoms suggesting brain metastases", "\u2022 Pulmonary dysfunction requiring the use of oxygen", "\u2022 Previous organ allogreffe requiring immunosuppression", "HIV is HIV-positive when taking combination antiretroviral therapy", "\u2022 Pre-existing neuropathy of grade 3 or 4", "- Hypersensitivity to halichondrin B or a chemical derivative of halichondrin B", "\u2022 Uncontrolled intercurrent disease", "\"Inability to read in English\""], "Results": ["Performance measures:", "Overall response rate (OR)", "By RECIST 1.1 for target lesions: RC is the complete elimination of all target lesions and PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference sum the LD. PR or a better overall response assumes a stable/minimum incomplete (SD) response/disease for the evaluation of non-target lesions and the absence of new lesions.", "Timeline: The disease was assessed radiologically at baseline and every 9 weeks after treatment; The maximum duration of treatment was 38 cycles/26 months (cohort 1) and 17 cycles/12 months (cohort 2)", "Results 1:", "Title of arm/group: Cohort 1: HR+/HER2-", "Description of the arm/group: Eribulin: 1.4 mg/m2 administered intravenously for 2-5 minutes on days 1 and 8 of each 21-day cycle", "The participants remained under a single agent, eribulin, until the disease progressed or retired for other reasons.", "Total number of participants analysed: 45", "Type of measurement: Number", "Unit of measure: percentage of participants 35.6 (24 to 49)", "Results 2:", "Title of the arm/group: Cohort 2: TNBC", "Description of the arm/group: Eribulin: 1.4 mg/m2 administered intravenously for 2-5 minutes on days 1 and 8 of each 21-day cycle", "The participants remained under a single agent, eribulin, until the disease progressed or retired for other reasons.", "Total number of participants analysed: 38", "Type of measurement: Number", "Unit of measure: percentage of participants 13.2 (5-26)"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/45 (48.89 per cent)", "Anemia 0/45 (0.00 %)", "- Febrile neutropenia 2/45 (4.44 per cent)", "Diarrhoea 1/45 (2.22%)", "Oral mucositis 1/45 (2.22%)", "Nausea 0/45 (0.00 %)", "Vomiting 1/45 (2.22%)", "Fatigue 1/45 (2.22%)", "- Lip infection 0/45 (0.00 %)", "Increased alkaline phosphatase 1/45 (2.22%)", "Increased aspartate aminotransferase 1/45 (2.22%)", "Decrease in lymphocyte count 1/45 (2.22%)", "Adverse Events 2:", "Total: 13/38 (34.21 per cent)", "Anemia 2/38 (5.26%)", "Febrile neutropenia 2/38 (5.26%)", "Diarrhoea 1/38 (2.63 per cent)", "- Oral mucositis 0/38 (0.00 %)", "Nausea 1/38 (2.63 per cent)", "- Vomiting 2/38 (5.26 per cent)", "- Fatigue 0/38 (0.00 %)", "1/38 (2.63%)", "Increase in alkaline phosphatase 0/38 (0.00 %)", "Increased aspartate aminotransferase 0/38 (0.00 %)", "- Decreased lymphocyte count 0/38 (0.00 %)"]}